DexCom(US:DXCM) Newsfile·2025-11-06 23:22Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, about the upcoming lead plaintiff deadline for a class action lawsuit set for December 29, 2025 [1]. Group 1: Class Action Details - Investors who bought DexCom securities during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by December 29, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its performance in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the company overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues [5]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal repercussions, leading to investor damages when the truth was revealed [5].